All LHID2005 files are available from the LHID2005 database (accession number(s) NHIRD-101-513).

Introduction {#sec005}
============

Chronic obstructive pulmonary disease (COPD) is a chronic progressive disease characterized by pulmonary function decline and persistent airway inflammation; its global prevalence is 5%--13%.\[[@pone.0203377.ref001], [@pone.0203377.ref002]\] It is also one of the most prevalent causes of mortality and is expected to have the third highest disease burden globally by 2020.\[[@pone.0203377.ref003], [@pone.0203377.ref004]\] Episodes of acute exacerbation are common among patients with COPD, and lead to pulmonary function decline, increased mortality and morbidity, and disability; they also increase the economic burden of health care expenditures faced by society.\[[@pone.0203377.ref005]--[@pone.0203377.ref008]\] In addition to the pulmonary system, COPD can affect nonrespiratory systems.\[[@pone.0203377.ref009], [@pone.0203377.ref010]\] For example, some previous studies have demonstrated that COPD patients are at a risk of lung cancer.\[[@pone.0203377.ref011]--[@pone.0203377.ref013]\] Another recent study reported that COPD can increase the risk of several extrapulmonary cancers.\[[@pone.0203377.ref014]\] These results suggest that COPD is associated with cancer; furthermore, patients with COPD are hypoxemic and exhibit systemic inflammation, which provide an advantageous environment for cancer development.\[[@pone.0203377.ref011], [@pone.0203377.ref015]\]

Prostate cancer is a slow and progressive disease, and is one of the most common cancers among men in Western countries.\[[@pone.0203377.ref016]\] Previous research has described many etiologies for prostate cancer, such as aging, family history, race, androgen, obesity, and chronic prostate inflammation.\[[@pone.0203377.ref017]--[@pone.0203377.ref019]\] In addition to local inflammation of the prostate, some recent studies have reported that systemic inflammation can induce the carcinogenesis of prostate cancer.\[[@pone.0203377.ref020], [@pone.0203377.ref021]\] Toriola et al. conducted a prospective cohort study with an average follow-up period of 24 years in Finland; they investigated the association of three common inflammatory markers (C-reactive protein, fibrinogen, and leukocyte count) with the risk of prostate cancer, and found that men with elevated leukocyte counts had a 2.57-fold increased risk of prostate cancer mortality.\[[@pone.0203377.ref020]\] Another previous study compared a single-nucleotide polymorphism between normal individuals and patients with prostate cancer, and determined that TLR1, TLR6, OAS1, and OAS2 genes, which are associated with innate inflammation pathways, were nominally associated with the risk of advanced prostate cancer.\[[@pone.0203377.ref021]\]

Both COPD and prostate cancer are chronic progressive diseases and critical public health challenges. As described earlier, inflammation is one of the factors contributing to the carcinogenesis of prostate cancer, and COPD is characterized by inflammation. A recent population-based study investigated a wide spectrum of cancer risk among patients with COPD, and revealed that these patients exhibited a 1.20-fold higher risk of prostate cancer than controls; however, risk factors such as smoking and obesity were not controlled for in that study.\[[@pone.0203377.ref022]\] A recent systemic review and meta-analysis indicated glutathione S-transferase T 1 (GSTT1) and glutathione S-transferase M 1 (GSTM1) polymorphisms are associated with increased risk of prostate cancer in Asians.\[[@pone.0203377.ref023]\] Thakur et al investigated the role of GSTM1 and GSTT1 null genotypes as risk factors for COPD and prostate cancer and found null genotype of GSTT1 2 fold significantly increased risk for COPD.\[[@pone.0203377.ref024]\] Moreover, the influence of inhaled pharmacotherapy used by patients with COPD on the risk of prostate cancer has not been analyzed. Therefore, we conducted a retrospective cohort study to investigate whether COPD is a risk factor for prostate cancer, and analyzed the effect of inhaled medication on the risk of prostate cancer in such patients.

Methods {#sec006}
=======

Study data {#sec007}
----------

Data for this study was collected from Taiwan's Longitudinal Health Insurance Database 2005 (LHID2005), which contains the claims data of 1 million residents of Taiwan; these residents account for approximately 5% of the total number of beneficiaries and were randomly selected from the insurants of the National Health Insurance (NHI) program of Taiwan. The NHI program, established on March 1, 1995, provides comprehensive medical care service coverage for more than 99% of residents of Taiwan. All NHI claims data is included in the National Health Insurance Research Database (NHIRD), which is maintained by the National Health Research Institutes and contains registration files and claims data for reimbursement. For research purposes and improving the quality of care in Taiwan, the LHID2005 was derived from the NHIRD. The LHID2005 contains information on age, sex, diagnoses made according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes, medication prescriptions, dosages, duration of medication usage, medical interventions (e.g., surgery), and medical expenditures.

Validation of the study data {#sec008}
----------------------------

Because the LHID2005 contains no information on body mass index (BMI), smoking, or alcohol drinking, which are important variables that affect patients with COPD and prostate cancer, we used the National Health Interview Survey (NHIS) database to acquire these variables as an external validation study. The NHIS is a nationwide cross-sectional health survey, and the NHIS2005 was conducted from April to August 2005 on residents of Taiwan by using a stratified sampling scheme. Detailed information on the NHIS is available in a previous study by Guo et al.\[[@pone.0203377.ref022]\]

Patients and study design {#sec009}
-------------------------

From January 1, 2004, to December 31, 2008, we conducted a longitudinal, retrospective, case--control cohort study to investigate whether COPD is a risk factor for prostate cancer. Both the study and control cohorts were identified from the LHID2005. The study cohort (COPD cohort) comprised patients with COPD who had records of ambulatory care visits for COPD treatment from January 1, 2004 to December 31, 2004. The COPD cohort comprised male patients who were older than 50 years, had had at least two consecutive diagnoses of COPD (ICD-9-CM codes 491, 492, and 496) before receiving COPD treatment in 2004, had at least three records of COPD pharmacotherapy in 2004, received stationary medication (no medication change) for COPD within the year of treatment initiation, and had no record of COPD medication 1 year before initiating treatment. The exclusion criteria of the study cohort were records of diagnostic codes for prostate cancer before 2004 and missing data in the LHID. The control cohort consisted of the remaining patients from the LHID2005, and was matched to the study cohort by age and sex in a 3:1 ratio. All patients enrolled in this study were followed up until the occurrence of prostate cancer, death, withdrawal from the NHI program (migration to another country or refusal to pay the fee of insurance), or December 31, 2008. The outcome of this study was prostate cancer development (ICD-9-CM code 185.XX) during the 4-year longitudinal follow-up period. Because the NHI program defines prostate cancer as a catastrophic illness, cancer-associated medical expenditures were waived. For catastrophic illness certification, in addition to clinical presentation and image evaluation, the diagnosis of prostate cancer depends on pathological proof. Thus, the diagnostic accuracy of prostate cancer is reliable in this study. The NHIRD deidentifies and encrypts data, thus ensuring patient privacy and that researchers cannot trace individual patients or health service providers by using the data. Therefore, this study was exempted from a complete review by any institutional review board.

Covariates of both cohorts {#sec010}
--------------------------

To determine the possible confounders related to the risk of prostate cancer, we calculated the Charlson Comorbidity Index (CCI) by following the comorbidities of both cohorts in this study: myocardial infarction (ICD-9-CM codes 410 and 412), congestive heart failure, peripheral vascular disease, cerebral vascular disease, dementia, rheumatic diseases (rheumatoid arthritis, ICD-9-CM code 714.0; systemic lupus erythematosus, ICD-9-CM code 710.0), peptic ulcer, liver diseases, renal disease, diabetes, metastatic carcinoma, and acquired immune deficiency syndrome.

Medication and inhaled pharmacotherapy for COPD {#sec011}
-----------------------------------------------

Using the LHID2005, we analyzed the use of the following medications in COPD patients: aspirin, statin, oral steroid, nonsteroidal anti-inflammatory drug (NSAID), and inhalation medicine. The prescribed inhalation medication was classified as follows: (1) short-acting muscarinic antagonists (SAMAs): ipratropium bromide metered-dose inhaler (MDI) (Atrovent, Boehringer Ingelheim); (2) short-acting β-agonists (SABAs): fenoterol hydrobromide MDI (Berotec, Boehringer Ingelheim), terbutaline sulfate Turbuhaler (Bricanyl, GlaxoSmithKline), or salbutamol sulfate MDI (Ventolin, GlaxoSmithKline); (3) long-acting muscarinic antagonists (LAMAs): tiotropium HandiHaler (Spiriva, Boehringer Ingelheim); (4) long-acting β-agonists (LABAs): formoterol Turbuhaler (Oxis, AstraZeneca) or salmeterol MDI (Serevent, GlaxoSmithKline); and (5) LABAs plus inhaled corticosteroids (ICSs): formoterol plus budesonide Turbuhaler (Symbicort, AstraZeneca) or salmeterol plus fluticasone MDI (Seretide, GlaxoSmithKline). The accumulated prescription duration for each claim of these inhaled pharmacotherapies must be longer than 14 days. For patients treated with regular long-acting inhalation medication (LAMAs, LABAs, or LABAs plus ICSs), the short-term use of SABAs or SAMAs as an on-demand rescue for acute exacerbation was allowed. Notably, patients with COPD using a combination of inhalation medication were excluded from this analysis. In addition to inhaled medicine, other medication such as aspirin, oral form of steroid, nonsteroidal anti-inflammatory drugs (NSAIDs), and the statins (included simvastatin (ATC code C10AA01), lovastatin (ATC code C10AA02), pravastatin (ATC code C10AA03), fluvastatin (ATC code C10AA04), and atorvastatin (ATC code C10AA05)) were analyzed in this study.

Statistical analyses {#sec012}
--------------------

All statistical analyses were performed using the SAS statistical package (version 9.1.3; SAS Institute, Cary, NC, USA). A p value of \<0.05 was considered statistically significant. The demographic data and comorbidities were analyzed using Pearson's chi-square test. As noted earlier, essential demographic data for prostate cancer, such as BMI, smoking, and alcohol drinking, could not be acquired from the main database (LHID2005). Based on the two-stage design, we combined patients from the main and validating databases to adjust for these missing confounders.\[[@pone.0203377.ref025]\] From the LHID2005, 12,774 patients with COPD were included in the study cohort, and 38,322 patients without COPD were included in the control cohort. ([Fig 1](#pone.0203377.g001){ref-type="fig"}) Another 312 patients with COPD and 804 patients without COPD were identified from the NHIS for the validation cohort. The incidence and hazard ratio (HR) were analyzed using a stratified Cox model to determine the risk of prostate cancer in the COPD cohort, in comparison with that in the control cohort. All demographic data, comorbidity, and COPD medication variables were analyzed in this model to calculate the adjusted HR for subsequent prostate cancer development. We also compared the demographic data and comorbidities of patients with or without prostate cancer in the COPD cohort by using Pearson's chi-square test. Finally, we used multivariable Cox proportional hazard regression to analyze the effect of COPD medication on the risk of prostate cancer in patients with COPD.

![Study flowchart.](pone.0203377.g001){#pone.0203377.g001}

Two-stage propensity score calibration approach {#sec013}
-----------------------------------------------

To determine the influence of the missing confounders of BMI, smoking, and alcohol drinking in the LHID2005, we adopted a two-stage approach that has been widely utilized to integrate different databases.\[[@pone.0203377.ref025], [@pone.0203377.ref026]\] Therefore, in this two-stage approach, which was described by Stürmer et al.,\[[@pone.0203377.ref026]\] the propensity score was used to adjust for the missing confounders acquired from the NHIS2005. The detailed statistic method procedures as follows: suppose that D denotes a COPD indicator variable. A value of 1 is selected for patients with COPD and 0 for patients without COPD. Let E be a matrix of observed confounders, namely age, sex, and Charlson Comorbidity Index (CCI). Let M denote an indicator for the missing confounders, smoking, alcohol consumption, and BMI.

1.  Let the probability PS = Pr (D = 1\|E) be a propensity score in the main study.

2.  The propensity score PS~c~ = Pr(D = 1\|*E*) is defined as the error-prone variable, and PS~*m*~ = Pr(*D* = 1\|*E*, *M*) is defined as the gold standard in the validation study.

3.  prostate cancer association in a Cox proportional hazard model is defined as H(t\|D,PS) = H~0~(*t*) exp{*βD* + *β*~*c*~*PS*}.

4.  The measurement error in the model is given by E(PS~*m*~\|*D*, PS~*c*~) = *γ*~0~ + *γD* + *γ*~*c*~PS~*c*~, The estimation of the parameter (*γ*~0~,*γ*~*c*~,*γ*) can be obtained by the least squares method of the regression equation.

5.  Both LHID and NHIS datasets from this study were sampled from the same population, the regression calibration after adjustment for E and M confounding factor estimator for the effect of E is given by $\hat{\beta^{*}} = \hat{\beta} - \Delta\hat{\gamma}$, where $\Delta = \frac{\hat{\beta_{c}}}{\hat{\gamma_{c}}}$. The parameter estimator ($\hat{\beta},\hat{\beta_{c}}$) can be obtained by step 3 Cox regression, and ($\hat{\gamma},\hat{\gamma_{c}}$) can be obtained by step 4 regression model.

The term $\hat{\beta^{*}}$ is estimated because of failure to adjust for missing confounders.

Bootstrap method for sensitively analysis {#sec014}
-----------------------------------------

We use bootstrap procedures for sensitively analysis, the bootstrap method simply resample from the empirical distribution. We present a formal algorithm. Let B denote the number of bootstrap replications. $\hat{\beta}$ be a estimator of β.

1.  Set B = 1000, j = 1.

2.  j ≤ B, then do 2 -- 5.

3.  Let S\* be the realization of a random sample drawn from study samples with replacement.

4.  Let $\hat{\beta}* = \hat{\beta}\left( S^{*} \right)$ be a estimator from Cox model with sample S\*.

5.  Let j = j+1

6.  Let ${\hat{\beta}}_{(1)}^{*} \leq {\hat{\beta}}_{(2)}^{*} \leq \ldots \leq {\hat{\beta}}_{(B)}^{*}$ denote the ordered of $\hat{\beta}*$. The percentile bootstrap 95% confidence interval for β is (${\hat{\beta}}_{(2.5\%*B)}^{*},{\hat{\beta}}_{(97.5\%*B)}^{*}$).

The framework of data analysis is presented as [Fig 2](#pone.0203377.g002){ref-type="fig"}.

![Data analysis framework.](pone.0203377.g002){#pone.0203377.g002}

Results {#sec015}
=======

As indicated by the LHID, the prevalence of comorbidities such as myocardial infarction (2.3%), congestive heart failure (16.3%), peripheral vascular disease (7.0%), and cerebrovascular disease (25.3%) was higher in the COPD cohort than in control cohort. Moreover, the validation database (NHIS) was used to acquire the missing confounders of alcohol drinking, smoking, and BMI in the main database of LHID ([Table 1](#pone.0203377.t001){ref-type="table"}). The incidence of prostate cancer was 633 per 100,000 person-years in the COPD cohort and 361 per 100,000 person-years in the control cohort. Compared with the control cohort, the crude HR was 1.75 (95% confidence interval \[CI\], 1.52--2.01, p \< 0.001), the adjusted HR (adjusted with patients' age and CCI) was 1.66 (95% CI, 1.44--1.91, p \< 0.001), and the propensity score calibration-adjusted HR (adjusted with patients' age, CCI, and the missing confounders of smoking, alcohol drinking, and BMI) was 1.62 (95% CI, 1.40--1.87, p \< 0.001) for the risk of prostate cancer in the COPD cohort ([Table 2](#pone.0203377.t002){ref-type="table"}). [Fig 3](#pone.0203377.g003){ref-type="fig"} displays the Kaplan--Meier hazard curves for the risk of prostate cancer in the COPD and control cohorts during the 4-year follow-up period. The sensitivity analysis of [Table 3](#pone.0203377.t003){ref-type="table"} revealed adjusted HR was 7.36 (Bootstrap 95% CI, 5.55--9.92, empirical p = 0.001) for 1 year of follow-up, 2.58 (Bootstrap 95% CI, 2.13--3.13, empirical p = 0.001) for 2 years of follow-up and 1.84 (Bootstrap 95% CI, 1.55--2.13, empirical p = 0.001) for 3 years of follow-up. [Table 4](#pone.0203377.t004){ref-type="table"} presents the demographic data and comorbidity prevalence of patients with or without prostate cancer in the COPD cohort. Notably, patients with COPD and prostate cancer were younger than patients with COPD but without prostate cancer, and as expected, patients with COPD and prostate cancer had a higher prevalence of metastatic cancer. Furthermore, the multivariate Cox proportional hazard regression revealed that the HR for prostate cancer was 1.61 (95% CI, 1.19--2.16, p = 0.002), 1.89 (95% CI, 1.40--2.54, p \< 0.001), 0.63 (95% CI, 0.45--0.89, p = 0.010), and 0.55 (95% CI, 0.35--0.85, p = 0.008) in patients with COPD using SAMAs, SABAs, statin, and aspirin, respectively ([Table 5](#pone.0203377.t005){ref-type="table"}). The [Fig 4](#pone.0203377.g004){ref-type="fig"} represented the risk of prostate cancer when using different medication among COPD patients by Kaplan-Meier hazard rates.

![Kaplan--Meier plot of hazard rates for prostate cancer in patients with COPD and gout and controls during the follow-up period of up to 4 years.](pone.0203377.g003){#pone.0203377.g003}

![Kaplan--Meier plot of hazard rates for prostate cancer of COPD patients with SABA, SAMA, aspirin and statin medication with up to 4 years of following period.](pone.0203377.g004){#pone.0203377.g004}

10.1371/journal.pone.0203377.t001

###### Demographic characteristics and Charlson comorbidity index for male patients with COPD and male patients without COPD in the LHID main database and NHIS validation database.

![](pone.0203377.t001){#pone.0203377.t001g}

                                                Main study (LHID)              Validation study (NHIS)                                                   
  --------------------------------------------- ------------------- ---------- ------------------------- ------- --------- ------ ------- ------ ------- ---------
  Age (years)                                                                                                    1                                       1
      51--60                                    2361                18.5       7083                      18.5              81     26.0    243    30.2    
      61--70                                    3069                24.0       9207                      24.0              71     22.8    213    26.5    
      \>70                                      7344                57**0**5   22,032                    57.5              160    51.3    348    43.3    
  Charlson Comorbidity Index (CCI)                                                                                                                       
  Myocardial Infarction                                                                                          0.003                                   0.043
      Yes                                       293                 2.3        716                       1.9               10     3.2     11     1.4     
      No                                        12,481              97.7       37,606                    98.1              302    96.8    798    98.6    
  Congestive Heart Failure                                                                                       \<0.001                                 \<0.001
      Yes                                       2082                16.3       2974                      7.8               47     15.1    53     6.6     
      No                                        10,692              83.7       35,348                    92.2              265    84.9    751    93.4    
  Peripheral Vascular Disease                                                                                    \<0.001                                 \<0.001
      Yes                                       895                 7.0        1909                      5.0               32     10.3    37     4.6     
      No                                        11,879              93.0       36,413                    95.0              280    89.7    767    95.4    
  Cerebrovascular Disease                                                                                        \<0.001                                 \<0.001
  Yes                                           3237                25.3       7020                      18.3              83     26.6    137    17.0    
  No                                            9537                74.7       31,302                    81.7              229    73.4    667    83.0    
  Dementia                                                                                                       \<0.001                                 0.330
  Yes                                           993                 7.8        1698                      4.4               17     5.4     33     4.1     
  No                                            11,781              92.2       36,624                    95.6              295    94.6    771    95.9    
  Connective Tissue Disease-Rheumatic Disease                                                                    \<0.001                                 0.222
  Yes                                           506                 4.0        914                       2.4               12     3.8     20     2.5     
  No                                            12,268              96.0       37,408                    97.6              300    96.2    784    97.5    
  Peptic Ulcer Disease                                                                                           \<0.001                                 \<0.001
  Yes                                           5122                40.1       10,036                    26.2              132    42.3    232    28.9    
  No                                            7652                59.9       28,286                    73.8              180    57.7    572    71.1    
  Mild Liver Disease                                                                                             \<0.001                                 0.039
  Yes                                           2956                23.1       6441                      16.8              78     25.0    156    19.4    
  No                                            9818                76.9       31,881                    83.2              234    75.0    648    80.6    
  Diabetes without Complications                                                                                 \<0.001                                 0.114
  Yes                                           2961                23.2       8292                      21.6              78     25.0    166    20.6    
  No                                            9813                76.8       30,030                    78.4              234    75.0    638    79.4    
  Diabetes with Complications                                                                                    0.675                                   0.329
  Yes                                           862                 6.7        2545                      6.6               15     4.8     51     6.3     
  No                                            11,912              93.3       35,777                    93.4              297    95.2    753    93.7    
  Paraplegia or Hemiplegia                                                                                       \<0.001                                 0.479
  Yes                                           235                 1.8        514                       1.3               7      2.2     13     1.6     
  No                                            12,539              98.2       37,808                    98.7              305    97.8    791    98.4    
  Renal Disease                                                                                                  \<0.001                                 0.421
  Yes                                           1052                8.2        2585                      6.7               21     6.7     44     5.5     
  No                                            11,722              91.8       35,737                    93.3              291    93.3    760    94.5    
  Moderate or Severe Liver Disease                                                                               0.340                                   0.691
  Yes                                           50                  0.4        128                       0.3               1      0.3     4      0.5     
  No                                            12,724              99.6       38,194                    99.7              311    99.7    800    99.5    
  Metastatic Carcinoma                                                                                           0.663                                   0.163
  Yes                                           78                  0.6        221                       0.6               4      1.3     4      0.5     
  No                                            12,696              99.4       38,101                    99.4              308    98.7    800    99.5    
  AIDS/HIV                                                                                                       0.004                                   Na
  Yes                                           9                   0.1        7                         0.0               0      0       0      0       
  No                                            12,765              99.9       38,315                    100.0             312    100     804    100     
  CCI Score (SD)                                1.7                 (1.5)      1**·**2                   (1.3)   \<0.001   1.7    (1.4)   1.2    (1.3)   
  Smoking                                                                                                                                                0.012
      Yes                                                                                                                  186    59.6    412    51.2    
      No                                                                                                                   126    40.4    392    48.8    
  Alcohol Drinking                                                                                                                                       0.151
      Yes                                                                                                                  107    34.3    313    38.9    
      No                                                                                                                   205    65.7    491    61.1    
  BMI (SD)                                                                                                                 23.4   (3.7)   24.2   (3.9)   0.002

COPD, chronic obstructive pulmonary disease

10.1371/journal.pone.0203377.t002

###### Crude and adjusted hazard ratios for prostate cancer in patients with COPD and patients without COPD during the 4-year follow-up period (n = 51,096).

![](pone.0203377.t002){#pone.0203377.t002g}

  -------------------------------------------------------------------------------------------------------
  Presence of prostate cancer                                  Non-COPD     COPD               P value
  ------------------------------------------------------------ ------------ ------------------ ----------
  Yes/Total                                                    550/38,322   318/12,774         \< 0.001

  Incidence (100,000 person-years)                             361          633                \< 0.001

  Crude HR (95% CI)                                            1.00         1.75(1.52--2.01)   \< 0.001

  Adjusted[^a^](#t002fn001){ref-type="table-fn"} HR (95% CI)   1.00         1.66(1.44--1.91)   \< 0.001

  Two-stage method\                                            1.00         1.62(1.40--1.87)   \< 0.001
  adjusted HR (95% CI)[^b^](#t002fn002){ref-type="table-fn"}                                   
  -------------------------------------------------------------------------------------------------------

^a^Adjustment for propensity score, including patients' age and Charlson Comorbidity Index (CCI).

^b^Adjustment for propensity score, including patients' age, Charlson Comorbidity Index (CCI), and the missing confounders of smoking, alcohol drinking, and body mass index.

10.1371/journal.pone.0203377.t003

###### Sensitivity analysis---Hazard ratio point estimates and bootstrap 95% CI for prostate between COPD and none-COPD patients.
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  -------------------------------------------------
  Presence of\          PID                 
  prostate cancer                           
  --------------------- ------ ------------ -------
  1 year of follow-up   7.36   5.55--9.92   0.001

  2 year of follow-up   2.58   2.13--3.13   0.001

  3 year of follow-up   1.84   1.55--2.13   0.001
  -------------------------------------------------

^A^ Adjustments are made for patient's, age, Charlson Comorbidity Index (CCI).

10.1371/journal.pone.0203377.t004

###### Characteristics of male patients with COPD with or without prostate cancer.
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  Variable                           COPD cohort (N = 12,774)   p value                        
  ---------------------------------- -------------------------- ------------- --------- ------ ---------
  Age (mean ± SD)                    70.3 ± 10.26               73.5 ± 8.00   \<0.001          
  Charlson Comorbidity Index (CCI)                                                             
  Myocardial Infarction                                                                        0.911
      Yes                            7                          2.2           286       2.3    
      No                             311                        97.8          12,170    97.7   
  Congestive Heart Failure                                                                     0.458
      Yes                            47                         14.8          2035      16.3   
      No                             271                        85.2          10,421    83.7   
  Peripheral Vascular Disease                                                                  0.776
      Yes                            21                         6.6           874       7.0    
      No                             297                        93.4          11,582    93.0   
  Cerebrovascular Disease                                                                      0.655
  Yes                                84                         26.4          3153      25.3   
  No                                 234                        73.6          9303      74.7   
  Dementia                                                                                     0.430
  Yes                                21                         6.6           972       7.8    
  No                                 297                        93.4          11,484    92.2   
  Rheumatic Disease                                                                            0.450
  Yes                                10                         3.1           496       4.0    
  No                                 308                        96.9          11,960    96.0   
  Peptic Ulcer                                                                                 0.148
  Yes                                140                        44.0          4982      40.0   
  No                                 178                        56.0          7474      60.0   
  Mild Liver Disease                                                                           0.197
  Yes                                64                         20.1          2892      23.2   
  No                                 254                        79.9          9564      76.8   
  Diabetes without Complications                                                               0.715
  Yes                                71                         22.3          2890      23.2   
  No                                 247                        77.7          9566      76.8   
  Diabetes with Complications                                                                  0.434
  Yes                                18                         5.7           844       6.8    
  No                                 300                        94.3          11,612    93.2   
  Paraplegia or Hemiplegia                                                                     0.950
  Yes                                6                          1.9           229       1.8    
  No                                 312                        98.1          1227      98.2   
  Renal Disease                                                                                0.431
  Yes                                30                         9.4           1022      8.2    
  No                                 288                        90.6          11,434    91.8   
  Moderate or Severe Liver Disease                                                             0.258
  Yes                                0                          0             50        0.4    
  No                                 318                        100           12,406    99.6   
  Metastatic Carcinoma                                                                         \<0.001
  Yes                                26                         8.2           52        0.4    
  No                                 292                        91.8          12,404    99.6   
  AIDS/HIV                                                                                     0.632
  Yes                                0                          0             9         0.1    
  No                                 318                        100           12,447    99.9   

10.1371/journal.pone.0203377.t005

###### Multivariate Cox proportional hazard regression for the presence of prostate cancer in male patients with COPD.
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  Presence of prostate cancer   HR     95% CI       p value
  ----------------------------- ------ ------------ ---------
  SAMA                          1.61   1.19--2.16   0.002
  SABA                          1.89   1.40--2.54   \<0.001
  LAMA                          0.94   0.63--1.39   0.763
  LABA                          0.95   0.35--2.58   0.924
  LABA plus ICS                 0.87   0.64--1.19   0.399
  Statin                        0.63   0.45--0.89   0.010
  Aspirin                       0.55   0.35--0.85   0.008
  Steroid                       0.80   0.60--1.06   0.127
  NSAID                         1.01   0.65--1.57   0.950
  CCI score                     0.97   0.89--1.06   0.458
  Age (continuous)              1.02   1.00--1.03   0.008

SAMA, short-acting muscarinic antagonists. SABA, short-acting beta-agonists. LAMA, long-acting muscarinic antagonists. LABA, long-acting beta-agonists. ICS, inhaled corticosteroids

Discussion {#sec016}
==========

Our population-based, retrospective, and longitudinal cohort study demonstrated that male patients with COPD had a 1.62-times higher risk of prostate cancer than those without COPD. Further analysis revealed that patients with COPD who regularly used SABAs or SAMAs had a higher risk of prostate cancer than those who did not use medications. In contrast to short-acting bronchodilators, statin and aspirin could lower the risk of prostate cancer in patients with COPD.

Previous studies have investigated the association of COPD with a wide spectrum of cancer risk.\[[@pone.0203377.ref014], [@pone.0203377.ref027]\] For example, Chiang et al. analyzed 50,875 patients with COPD and found increased risks of incident cancers, including lung and mediastinal cancer, head and neck cancer, breast cancer, prostate cancer, central nervous system (CNS) cancer, lymphoma, and multiple myeloma. They also found that patients with COPD had a 1.2-times higher risk of prostate cancer.\[[@pone.0203377.ref014]\] Similarly, Ho et al. investigated the risk of cancer in 13,289 patients, and demonstrated higher risks of lung, liver, colorectal, breast, prostate, and stomach cancers in those patients with COPD than in those patients without COPD.\[[@pone.0203377.ref027]\]

Nevertheless, the definitive mechanism of carcinogenesis in patients with COPD is still subject to debate. Previous research has indicated that chronic inflammatory status and hypoxia-induced oxidative stress can lead carcinogenesis.\[[@pone.0203377.ref028]--[@pone.0203377.ref030]\] Moreover, chronic inflammation and hypoxic status have been observed in patients with COPD.\[[@pone.0203377.ref011], [@pone.0203377.ref031], [@pone.0203377.ref032]\] Therefore, we hypothesized that these factors could be one of the possible mechanisms of carcinogenesis in patients with COPD. Prior scholarship has also indicated that both prostate-localized inflammation and systemic inflammation can induce the carcinogenesis of prostate cancer.\[[@pone.0203377.ref019]--[@pone.0203377.ref021]\] In contrast to inflammation, which can put patients with COPD at risk for prostate cancer, the endocrinology aspect may be a protective factor in male patients with COPD. Previous studies have noted that androgens are required for prostate gland growth and development, and are considered to be key risk factors for prostate cancer.\[[@pone.0203377.ref033], [@pone.0203377.ref034]\] Another recent cross-sectional study compared 69 male patients with COPD with 82 healthy volunteers, and found a significant reduction in total and free testosterone in the patients with COPD.\[[@pone.0203377.ref035]\] However, this finding is inconsistent with our study results. Similarly, one previous study investigated the association between endogenous sex hormones and prostate cancer by analyzing 18 prospective studies, and indicated no association between testosterone and the risk of prostate cancer.\[[@pone.0203377.ref036]\] Therefore, although the testosterone level is lower in patients with COPD, they still have a higher risk of prostate cancer, and the influence of testosterone on prostate cancer remains controversial.

Our study analyzed the inhaled medication used by patients with COPD and demonstrated that short-acting bronchodilators, such as SABAs and SAMAs, can increase the risk of prostate cancer in patients with COPD. Short-acting inhaled bronchodilators are often taken as rescue medicine for the acute exacerbation of COPD. Our study also revealed a higher risk of prostate cancer in patients with COPD who use two types of short-acting bronchodilators ([Fig 4](#pone.0203377.g004){ref-type="fig"}). However, long-acting bronchodilators, which exhibit the same action mechanism as that of β-agonists (LABAs) and muscarinic antagonists (LAMAs), did not increase the risk of prostate cancer in patients with COPD. According to the assessment of exacerbation history and the status of airflow limitation, inhaled long-acting bronchodilators along or combined with ICSs are prescribed to patients with moderate to severe COPD.\[[@pone.0203377.ref002]\] Moreover, two large-scale, randomized, double-blind clinical trials demonstrated that long-acting bronchodilators with or without inhaled steroids can improve pulmonary function and quality of life, and decrease the acute exacerbations of COPD during the 4-year follow-up period.\[[@pone.0203377.ref037], [@pone.0203377.ref038]\]

Long-acting inhaled bronchodilators modulate the inflammation process in patients with COPD; such modulation may be a reason for the lower risk of prostate cancer in patients with COPD who use long-acting bronchodilators, compared with those who use short-acting bronchodilators. Short-acting bronchodilators are often prescribed alone for less severe COPD cases and are taken to relieve COPD symptoms. However, they cannot relieve the inflammatory status in patients with COPD, and the chronic systemic inflammatory characteristics may increase the risk of prostate cancer. Previous studies have found that the use of long-acting bronchodilators with inhaled steroids can decrease systemic inflammation, as demonstrated by decreased C-reactive protein (CRP) and interleukin-6 levels in patients with COPD.\[[@pone.0203377.ref039], [@pone.0203377.ref040]\] We hypothesized that inflammation control in patients with COPD may be crucial for protecting such individuals against subsequent prostate cancer development.

In recent years, increasing evidence has demonstrated that statin use reduces the risk of prostate cancer.\[[@pone.0203377.ref041]\] Cell and animal models have been used to investigate the molecular mechanisms through which statins inhibit the development of prostate cancer. One prior study investigated the immunomodulatory effects of statin, and found that statins suppressed the inflammatory process of CNS, which may be a protective mechanism through which statins lower the risk of prostate cancer.\[[@pone.0203377.ref042]\] Statins can also inhibit the angiogenesis and adhesion of prostate cancer cells and induce the apoptosis and cell growth arrest of these cells.\[[@pone.0203377.ref042]--[@pone.0203377.ref044]\] These findings support the present study results, which revealed that patients with COPD using statin had a lower risk of prostate cancer. Our study also found that COPD patients using aspirin had a lower risk of prostate cancer. A systemic review and meta-analysis found that aspirin can decrease prostate cancer incidence and mortality,\[[@pone.0203377.ref045]\] and another previous study demonstrated that the anti-inflammatory and antiplatelet effects of aspirin facilitate cancer prevention.\[[@pone.0203377.ref046]\] One recent report indicated that overexpression of prostaglandin and the cyclo-oxygenase enzyme could induce prostate cancer.\[[@pone.0203377.ref047]\] We hypothesized that aspirin can inhibit the cyclo-oxygenase enzyme, and therefore decrease the risk of prostate cancer in patients with COPD.

The strength of this study is in its large sample size, and the fact that it acquired the missing confounders (alcohol drinking, smoking, and BMI) from the NHIS. These confounders are important for patients with COPD and have not been presented by other NHIRD research in Taiwan. Nevertheless, this study has some limitations. First, similar to most NHIRD research, the diagnoses of COPD and prostate cancer were determined by clinicians; thus, the diagnostic accuracy should be verified. To correctly identify patients with COPD for their inclusion in the study cohort, we only enrolled patients with at least 3 consecutive claims records of related pharmacotherapy. Moreover, the National Health Insurance Administration in Taiwan randomly and regularly assigns specialists to review medical charts to verify diagnostic accuracy and correlated medical payment. No laboratory data on prostate-specific antigen are available, and imaging studies and histology findings cannot be obtained from the database. However, the coding for prostate cancer is strictly evaluated because prostate cancer coding indicates that patients have a catastrophic illness; thus, any prostate-cancer-related medical expenditure is waived. Second, the severity of COPD and patients' prostate cancer stages could not be represented in this study. The pulmonary function test data of patients with COPD were limited; thus, it was difficult to determine the association of COPD severity with the risk of prostate cancer. Further investigation of the stratified severity of COPD and the risk of prostate cancer is warranted. Third, we didn't enrolled COPD patients with multi-inhalation medication with consideration of drug and drug interaction when analyzing the risk of prostate cancer. These patients could be more severe than participants in study cohort and at higher risk of other co-morbidities such as cancer. Finally, medication used by COPD patients was determined using prescription claims from the database, and information on medication compliance is not available in this database. To accurately analyze the effect of COPD medication on the risk of prostate cancer, only patients with at least three records of prescription claims without changes in inhaled medication within 1 year were included in the study cohort. We considered these patients to have adhered to their medication prescriptions, indicating a reliable medication compliance in this study.
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Our large-scale, retrospective, case--control cohort study demonstrated that patients with COPD are at a higher risk of prostate cancer, particularly those using SAMAs or SABAs. We hypothesized that chronic inflammation may be a predisposing factor for the pathogenesis of prostate cancer. Our study also found that aspirin and statin could decrease the risk of prostate cancer in patients with COPD. This finding implies that inflammation control may decrease the risk of prostate cancer. Controlling chronic inflammation in patients with COPD may be a key prevention factor for prostate cancer. Further comprehensive prospective research of the correlation between COPD severity and the risk of prostate cancer, and prognosis with medication, is recommended.
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